Berenberg starts Italy's Pharmanutra with 'buy' expecting greater visibility

Pharmanutra SpA

02/10/2025 09:17

**  Berenberg starts coverage of the Italian healthcare group Pharmanutra PHNU.MI with a "buy" rating, expecting greater visibility from the upcoming quarter

** "We see conditions aligning for investors to reassess the equity story, as upcoming quarters should provide greater visibility on new strategic initiatives in the US and China", Berenberg says

** The broker cites Pharmanutra's leadership in oral iron supplements and transformational growth potential, highlighting the flagship Sideral brand's dominance in Italy

** Berenberg sets a PT of 85.00 euros, implying over 100% upside, and sees a re-rating potential as international growth accelerates

** Shares in the company rise about 9%, reducing YTD losses to about 22%

($1 = 0.8514 euros)

(Reporting by Laura Contemori)

((Laura.contemori@thomsonreuters.com))